Article
Dual actionability of BMI1 activation and mitotic vulnerability defines adaptive Osimertinib resistance in EGFR-mutant NSCLC.
Cell death & disease - 10 Jun 2026
Armanetti Paolo, Cabrera San Millan Eva, Di Nardo Maddalena, Mercatelli Raffaella, Cavallini Chiara, Crucitta Stefania, Del Re Marzia, Chiodi Alice, Mosca Ettore, Consiglio Arianna, Losito Nicola, Musio Antonio, Menichetti Luca, Bramanti Emilia, Ali Azhar, Levantini Elena, Maroni Giorgia
Abstract excerpt
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide. Tumors carrying activating epidermal growth factor receptor (EGFR) mutations initially respond to tyrosine kinase inhibitors (TKIs), with Osimertinib representing the current standard of care. However, acquired resistance inevitably develops, involving both genetic and non-genetic mechanisms, the latter playing a major role...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.